Shortages of essential cancer medicines: who is responsible and what are the possible solutions?

Lancet Oncol. 2024 Jan;25(1):23-26. doi: 10.1016/S1470-2045(23)00470-9.

Authors

Kristina Jenei¹, Mark P Lythgoe², Kerstin N Vokinger³

Affiliations

¹ London School of Economics, and Political Science, London WC2A 2AE, UK. Electronic address: k.jenei@lse.ac.uk.
² Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.
³ Faculty of Law and Faculty of Medicine, University of Zurich, Zurich, Switzerland.

PMID: 38181805
DOI: 10.1016/S1470-2045(23)00470-9

No abstract available

MeSH terms

Antineoplastic Agents* / supply & distribution
Humans
Neoplasms* / drug therapy

Substances

Antineoplastic Agents